Search the Newsreel

Colgate-Palmolive Q2 Earnings Call Highlights

Key Points Interested in Colgate-Palmolive Company? Here are five stocks we like better. Colgate-Palmolive delivered broad-based Q2 growth, with organic sales increasing across most divisions, gross margin expanding 100 basis points and free cash flow rising 18%. The company returned $1.4 billion to shareholders …

Colgate outlines 2026 gross margin as roughly flat as it expects higher raw materials and tariffs in H2

Earnings Call Insights: Colgate-Palmolive (CL) Q2 2026 MANAGEMENT VIEW * "We’re pleased to have delivered another quarter of strong top and bottom line growth, particularly in the context of continued global volatility," said (Chairman, CEO & President Noel Wallace), adding that results were "broad-based …

Moleculin Biotech (Nasdaq:MBRX) - Stock Analysis

Moleculin Biotech (MBRX) is a late-stage pharmaceutical company developing therapies for tumors and viruses, with its lead drug Annamycin undergoing Phase 2/3 trials for relapsed or refractory acute myeloid leukemia (R/R AML) and soft tissue sarcoma lung metastases. The company faces significant financial risks, …

Moleculin Biotech prices $9.3 million public offering

Moleculin Biotech (NASDAQ:MBRX) has priced a public offering of 12,376,667 shares of common stock and warrants for an additional 37,130,001 shares at $0.75 per share and warrant, totaling $9.3 million. The company plans to use the net proceeds to advance its lead drug candidate, …

Moleculin Announces Pricing of $9.3 Million Public Offering

Moleculin Biotech, Inc. announced the pricing of a $9.3 million public offering, selling 12,376,667 shares of common stock (or pre-funded warrants) and warrants to purchase up to 37,130,001 shares at $0.75 per unit. The offering is expected to close around August 3, 2026, with …

B. Riley Initiates 4D Molecular Therapeutics at Buy With $37 Price Target

B. Riley has initiated coverage on 4D Molecular Therapeutics (FDMT) with a "Buy" rating and a price target of $37. The company, a late-stage biotechnology firm, is advancing several therapeutic candidates, including 4D-150 for wet age-related macular degeneration and diabetic macular edema, and 4D-710 …

Colgate-Palmolive (CL) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

For the quarter ended June 2026, Colgate-Palmolive (CL) reported revenue of $5.36 billion, up 4.9% over the same period last year. EPS came in at $0.99, compared to $0.92 in the year-ago quarter. The reported revenue represents a surprise of +0.2% over the Zacks …

Colgate-Palmolive hält an Gewinnprognose für das Gesamtjahr 2026 fest

Colgate-Palmolive reaffirms annual sales forecast on weak North America demand

Colgate-Palmolive affirmed its annual

Moleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients

Moleculin Biotech announced positive interim blinded results from Part A of its pivotal Phase 2/3 MIRACLE trial for Annamycin in combination with cytarabine (AnnAraC) for relapsed or refractory AML. The trial showed a 37% composite complete remission (CRc) rate, with essentially identical rates for …

12 Health Care Stocks Moving In Friday's Pre-Market Session

This article identifies 12 healthcare stocks experiencing significant movement in pre-market trading on Friday. It lists several gainers, including Replimune Group and Moleculin Biotech, which saw substantial increases, and notable decliners such as Karyopharm Therapeutics and Bioage Labs. The movements are attributed to various …

Colgate-Palmolive (CL) Q2 2026 Earnings

Colgate-Palmolive (CL) reported strong Q2 2026 earnings, beating EPS estimates by 4.5% with $0.99, extending its beat streak to five quarters. The company's revenue of $5.36 billion met expectations, and it saw accelerating volume growth despite a sales decline in North America. Following these …

Colgate-Palmolive tops EPS estimates, but shares dip

Investing.com -- Colgate-Palmolive Company (NYSE:CL) reported second-quarter earnings before the open on Friday, topping earnings expectations. Adjusted earnings per share of $0.99 beat the analyst estimate of $0.95 by $0.04. Revenue for the quarter came in at $5.36 billion, matching the consensus estimate and …

Insight Molecular Diagnostics Inc. Revenue Breakdown – NASDAQ:IMDX

Insight Molecular Diagnostics Inc. (IMDX) generated $4.05 million USD last year, primarily from its Diagnostic Tests segment. The United States was the largest contributor to this revenue, accounting for $4.03 million USD. This represents a significant increase from the previous year's figures of $1.88 …

Colgate-Palmolive (CL) Q2 Earnings and Revenues Top Estimates

Colgate-Palmolive (CL) reported strong Q2 earnings, beating Zacks Consensus Estimates with $0.99 per share and revenues of $5.36 billion. The company has consistently surpassed EPS estimates over the last four quarters and seen its shares gain 15.9% year-to-date, outperforming the S&P 500. While its …

Colgate-Palmolive Sales Rise Despite Choppy Backdrop

Colgate-Palmolive reported increased sales in the second quarter, despite a challenging consumer market. The company's revenue grew by 4.9% to $5.36 billion. However, its profit declined to $693 million, or 86 cents per share, from $743 million, or 91 cents per share, in the …

Colgate-Palmolive supera las estimativas de BPA, pero sus acciones caen

Colgate-Palmolive (NYSE:CL) Posts Q2 CY2026 Sales In Line With Estimates

Colgate-Palmolive (NYSE:CL) Posts Q2 CY2026 Sales In Line With Estimates Consumer products company Colgate-Palmolive (NYSE:CL) met Wall Street's revenue expectations in Q2 CY2026, with sales up 4.9% year on year to $5.36 billion. Its non-GAAP profit of $0.99 per share was 4.5% above analysts' …

Colgate-Palmolive superaron 0.04$ las previsiones de BPA en el segundo trimestre del año

Colgate-Palmolive supera por 0,04$ las previsiones de BPA en el segundo trimestre del año

Colgate keeps 2026 sales outlook, lifts non-GAAP EPS growth

Colgate-Palmolive (NYSE: CL) announced its second-quarter 2026 results, showing a 4.9% increase in net sales and a 2.4% organic sales growth, despite a 5% GAAP EPS decrease. The company maintained its full-year 2026 net sales and GAAP EPS guidance but upgraded its non-GAAP (Base …

Colgate-Palmolive (CL) Tops Q2 EPS by 4c; Offers Guidance

Colgate-Palmolive (CL) reported strong Q2 earnings, surpassing analyst estimates by $0.04 with an EPS of $0.99 and meeting revenue expectations at $5.36 billion. The company also provided its full-year 2026 guidance, expecting net sales to be up 2% to 6% and organic sales growth …

Colgate Announces 2nd Quarter 2026 Results

NEW YORK, July 31, 2026--(BUSINESS WIRE)--Colgate-Palmolive Company (NYSE:CL): Net sales increased 4.9%; Organic sales* increased 2.4%, including a 0.4% negative impact from lower private label pet food sales GAAP EPS decreased 5% to $0.86; Base Business EPS* increased 8% to $0.99 GAAP Gross profit …

Shandong Molong Raises Registered Capital After H-Share Placement

Colgate-Palmolive Company $CL Shares Sold by South Dakota Investment Council

The South Dakota Investment Council reduced its stake in Colgate-Palmolive Company (NYSE:CL) by 29.2% in the first quarter, selling over 31,000 shares but retaining 76,661 shares valued at $6.5 million. Despite this institutional selling, analysts generally maintain a "Moderate Buy" rating with an average …

Groupe la Francaise Boosts Stock Holdings in Colgate-Palmolive Company $CL

Groupe la Francaise significantly increased its stake in Colgate-Palmolive Company (NYSE:CL) by 295.3% in the first quarter, now owning 138,723 shares valued at $11.666 million. Other institutional investors like Norges Bank and Bank of New York Mellon Corp also adjusted their holdings. The article …

Colgate-Palmolive Company $CL Shares Sold by Empowered Funds LLC

Empowered Funds LLC reduced its stake in Colgate-Palmolive Company (NYSE:CL) by 21.2% in the first quarter, selling 35,005 shares and bringing its total holdings to 130,068 shares valued at $11.086 million. Despite this, other institutional investors like Quantinno Capital Management LP and Lazard Asset …

B.Riley initiates 4D Molecular Therapeutics stock coverage with buy rating

B.Riley has initiated coverage on 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy rating and a price target of $37.00, suggesting substantial upside from its current price and indicating it may be undervalued. The firm views the company's lead candidate, 4D-150, for neovascular AMD as …

Colgate-Palmolive Lifts FY26 Adj. Earnings View, Despite Weak Q2 Profit; Stock Down

Colgate-Palmolive reported a weak Q2 profit despite higher net sales but confirmed its fiscal 2026 outlook for earnings and sales growth, while lifting guidance for Base Business earnings per share and gross profit margin. The company's shares were down approximately 2.78% in pre-market trading. …

Colgate-Palmolive falls after reporting soft organic sales in North America (CL:NYSE)

Colgate-Palmolive (CL) shares declined after its Q2 earnings report revealed a 4.9% revenue increase to $5.36 billion. However, organic sales growth was a softer 2.4%, impacted negatively by lower private label pet food sales. The report indicated some softness in North American organic sales.

Meghmani Organics Q1 Results FY27: PAT Rs 48 Cr, Revenue Rs 542 Cr

Colgate-Palmolive supera estimativas de LPA, mas ações recuam - Investing.com Brasil

Colgate-Palmolive Aktie: Zahlen schlagen, Kurs fällt

Top Wall Street Forecasters Revamp Colgate-Palmolive Expectations Ahead Of Q2 Earnings

Ahead of its Q2 earnings report on Friday, July 31, Colgate-Palmolive (NYSE: CL) is expected to report quarterly earnings of 95 cents per share and revenue of $5.36 billion. Several Wall Street analysts have recently updated their ratings and price targets for the company, …

Shandong Molong Raises HK$115.7 Million Through H-Share Placement

Colgate earnings up next: Can premium products lift margins? By Investing.com

Colgate-Palmolive (CL) is set to report its second-quarter earnings, with analysts expecting $0.95 EPS and $5.36 billion in revenue. Investors will focus on the company's ability to drive margins through premium products and manage volume versus pricing dynamics, especially after a strong first quarter. …